Five Prime Therapeutics doses first patient in phase 1b trial of FPA150
Five Prime Therapeutics announced that it initiated patient dosing in the Phase 1b dose expansion portion of the Phase 1a/1b clinical trial of FPA150 (FPA150-001; NCT03514121), a first-in-class immuno-oncology antibody that targets B7-H4. February 20, 2019